| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d678594bd077383f3fc87c8676ab3ae6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c909ba0bf007a2722c67e76d7bc6a138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9adfd8615849e9c22cdc691df7f8b6ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_af0f6e2e82292cb4dc0d93cdb37fb196 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-763
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2005-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5837789a57ba37775eea89624c7d362b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e6b002aecd15ce3ffb0c02c8ad4543f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24f5710b1e3188a97ed24cf8ba4483db |
| publicationDate |
2006-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006051636-A1 |
| titleOfInvention |
Drugs for treating rett syndrome |
| abstract |
A drug for treating Rett syndrome which comprises an expression vector containing MeCP2 gene as the active ingredient. The term “expression vector” as used herein means either a viral vector or a nonviral vector. A drug for treating Rett syndrome which comprises, as the active ingredient, a substance capable of repairing a mutation site in MeCP2 gene on a chromosome having mutated. A drug for treating Rett syndrome which comprises, as the active ingredient, a substance capable of artificially activating and expressing normal MeCP2 gene serving as an allele on the other X chromosome being nonfunctional due to the chromosome inactivation (X inactivation) mechanism. In these drugs, the gene expression and repair are carried out in the striatum (putamen) in the cranial nerve. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011101881-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IT-RM20100063-A1 |
| priorityDate |
2004-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |